• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Is that drug ad for me? Peo­ple pay more at­ten­tion to phar­ma DTC for fa­mil­iar con­di­tions, study finds

4 years ago
Pharma
Marketing

On­ly a pawn in their game: Or­phan drug tax cred­it on the chop­ping block again un­der Dem spend­ing bill

4 years ago
FDA+

Scoop: Eli Lil­ly and AC Im­mune qui­et­ly scrapped Alzheimer’s stud­ies for the cen­ter­piece of $2B deal months ago

4 years ago
Deals
R&D

Al­ny­lam’s John Maraganore isn’t the on­ly CEO to leave his post; CRISPR’s chief com­mer­cial of­fi­cer takes the ...

4 years ago
Peer Review

'I want to be a grand­dad': Why John Maraganore left and where he (and Al­ny­lam) are go­ing

4 years ago
People

A month af­ter Bio­con was hand­ed a Form 483, doc­u­ments re­veal lack­lus­ter con­di­tions

4 years ago
Manufacturing

Rid­ing Covid-19 high, As­pen plans new ad­di­tions at South African pro­duc­tion site

4 years ago
Manufacturing

Gene ther­a­py start­up Jaguar set to join NC man­u­fac­tur­ing boom with $125M fa­cil­i­ty

4 years ago
Manufacturing

De­spite FDA go-ahead, Emer­gent still sits on mil­lions of J&J vac­cine dos­es — re­port

4 years ago
Coronavirus
Manufacturing

Catal­ent widens its am­bi­tious ex­pan­sion at Bal­ti­more air­port site, adding more vi­ral vec­tor suites

4 years ago
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Biden pumps $500M in­to do­mes­tic test­ing pro­duc­tion; Val­ne­va mulls pro­duc­tion deal

4 years ago
Coronavirus
Manufacturing

Ahead of clos­ing $11.5B Ac­celeron buy­out, Mer­ck is on the hunt for more deals

4 years ago
R&D

Small biotech whiffs bad­ly in PhI­II pan­cre­at­ic can­cer study, prompt­ing halt of an­oth­er late-stage tri­al

4 years ago
R&D

Look­ing to win back in­vestor con­fi­dence, Bio­Marin preps for its ‘largest launch’

4 years ago
Pharma
Marketing

White House kills off ma­jor drug pric­ing re­forms as De­moc­rats fail to co­a­lesce around Medicare ne­go­ti­a­tion plan

4 years ago
Pharma

In a sur­prise de­par­ture, Al­ny­lam's found­ing CEO John Maraganore is leav­ing the com­pa­ny — shares crater

4 years ago
People

A pair of part­ners at Fra­zier is fol­low­ing ear­ly-stage biotechs to the pub­lic mar­ket with an $830M fund. And they're ...

4 years ago
Financing

Check­mate CEO hits the ex­it as Art Krieg's crew strug­gles to warm in­vestors to TLR9 strat­e­gy

4 years ago
People

Covid-19 roundup: US buys 50M Pfiz­er pe­di­atric dos­es; Vir and GSK pub­lish mAb da­ta in NE­JM

4 years ago
Coronavirus

No­var­tis in hot wa­ter again over al­leged kick­backs, re­veal­ing new DoJ probe re­lat­ed to En­tresto

4 years ago
Pharma

Cheap SS­RI drug proves suc­cess­ful in re­duc­ing Covid-re­lat­ed hos­pi­tal­iza­tion times in large tri­al

4 years ago
R&D
Coronavirus

No­vavax takes pro­tein-based Covid-19 vac­cine over­seas, ask­ing for an ap­proval in the UK

4 years ago
Coronavirus

Koch leads mam­moth $215M in­fu­sion in­to AI start­up boast­ing 'largest data­base' of im­mune cells

4 years ago
Financing
AI

Pfiz­er, No­var­tis, Janssen and oth­er biotechs sign on­to NIH/FDA pro­gram to de­vel­op new gene ther­a­pies for rare ...

4 years ago
Cell/Gene Tx
FDA+
First page Previous page 621622623624625626627 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times